GIM
ENTA icon

Granahan Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Granahan Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-43,414
Closed -$3.09M – 180
2022
Q1 		$3.09M Sell
43,414
-141,997
-77% -$9.24M 0.08% 155
2021
Q4 		$13.9M Buy
185,411
+2,595
+1% +$204K 0.29% 97
2021
Q3 		$10.4M Sell
182,816
-17,154
-9% -$848K 0.2% 109
2021
Q2 		$8.8M Buy
199,970
+6,554
+3% +$321K 0.16% 120
2021
Q1 		$9.54M Sell
193,416
-37,655
-16% -$1.88M 0.2% 95
2020
Q4 		$9.73M Buy
231,071
+42,907
+23% +$1.89M 0.22% 94
2020
Q3 		$8.61M Sell
188,164
-17,236
-8% -$835K 0.29% 83
2020
Q2 		$10.3M Buy
205,400
+56,800
+38% +$2.94M 0.37% 76
2020
Q1 		$7.64M Sell
148,600
-693
-0.5% -$36.9K 0.41% 64
2019
Q4 		$9.22M Buy
149,293
+689
+0.5% +$42.7K 0.42% 68
2019
Q3 		$8.93M Buy
148,604
+4,805
+3% +$357K 0.49% 62
2019
Q2 		$12.1M Sell
143,799
-7,523
-5% -$677K 0.6% 47
2019
Q1 		$14.5M Sell
151,322
-685
-0.5% -$61.4K 0.78% 41
2018
Q4 		$10.8M Buy
152,007
+48,687
+47% +$3.73M 0.76% 45
2018
Q3 		$8.83M Buy
103,320
+2,650
+3% +$265K 0.48% 68
2018
Q2 		$11.7M Buy
100,670
+7,763
+8% +$775K 0.7% 44
2018
Q1 		$7.52M Buy
92,907
+3,096
+3% +$238K 0.54% 60
2017
Q4 		$5.27M Sell
89,811
-12,230
-12% -$612K 0.41% 86
2017
Q3 		$4.78M Sell
102,041
-49,654
-33% -$2M 0.4% 91
2017
Q2 		$5.46M Sell
151,695
-45,713
-23% -$1.46M 0.5% 75
2017
Q1 		$6.08M Sell
197,408
-298,617
-60% -$9.3M 0.61% 58
2016
Q4 		$16.6M Buy
496,025
+24,890
+5% +$713K 0.57% 71
2016
Q3 		$12.5M Buy
471,135
+57,720
+14% +$1.34M 0.41% 104
2016
Q2 		$9.12M Sell
413,415
-3,010
-0.7% -$78.8K 0.33% 114
2016
Q1 		$12.2M Buy
416,425
+63,400
+18% +$1.77M 0.44% 81
2015
Q4 		$11.7M Sell
353,025
-50,405
-12% -$1.64M 0.4% 93
2015
Q3 		$14.6M Buy
403,430
+168,300
+72% +$7.23M 0.45% 79
2015
Q2 		$10.6M Buy
+235,130
New +$9.15M 0.3% 120

Other funds holding ENTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Granahan Investment Management's ENTA Position: Q2 2022 in Review

Granahan Investment Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2022, closing a stake of 43,414 shares — an estimated $3.09M sold.

Granahan Investment Management first reported a position in ENTA in Q2 2015 and held it in 28 quarters. The position peaked at $16.6M in Q4 2016. 155 funds tracked by Wall St. Rank hold ENTA as of Q2 2022.

  • Granahan Investment Management reported no remaining Enanta Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Granahan Investment Management sold 43,414 Enanta Pharmaceuticals shares in Q2 2022, an estimated $3.09M.
  • Granahan Investment Management first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 28 quarters.
  • Granahan Investment Management's Enanta Pharmaceuticals position peaked at $16.6M in Q4 2016.
  • 155 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2022.

Based on Granahan Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.